HCWB HCW Biologics Inc

Price (delayed)

$0.629

Market cap

$23.79M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.76

Enterprise value

$27.98M

Highlights
HCWB's revenue has surged by 107% since the previous quarter and by 44% year-on-year
HCW Biologics's gross profit has soared by 107% from the previous quarter and by 44% YoY
HCW Biologics's quick ratio has shrunk by 94% YoY and by 34% QoQ
HCW Biologics's equity has plunged by 73% YoY and by 35% from the previous quarter

Key stats

What are the main financial stats of HCWB
Market
Shares outstanding
37.82M
Market cap
$23.79M
Enterprise value
$27.98M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.59
Price to sales (P/S)
20.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.07
Earnings
Revenue
$1.16M
EBIT
-$27.2M
EBITDA
-$26.12M
Free cash flow
-$28.51M
Per share
EPS
-$0.76
Free cash flow per share
-$0.77
Book value per share
$0.24
Revenue per share
$0.03
TBVPS
$0.82
Balance sheet
Total assets
$30.43M
Total liabilities
$21.69M
Debt
$8.27M
Equity
$8.74M
Working capital
-$7.2M
Liquidity
Debt to equity
0.95
Current ratio
0.46
Quick ratio
0.39
Net debt/EBITDA
-0.16
Margins
EBITDA margin
-2,246.9%
Gross margin
100%
Net margin
-2,356.1%
Operating margin
-2,395.6%
Efficiency
Return on assets
-81.7%
Return on equity
-146.8%
Return on invested capital
-105.8%
Return on capital employed
-159.9%
Return on sales
-2,339.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HCWB stock price

How has the HCW Biologics stock price performed over time
Intraday
6.61%
1 week
-8.84%
1 month
-12.64%
1 year
-71.15%
YTD
-48.65%
QTD
-3.23%

Financial performance

How have HCW Biologics's revenue and profit performed over time
Revenue
$1.16M
Gross profit
$1.16M
Operating income
-$27.85M
Net income
-$27.39M
Gross margin
100%
Net margin
-2,356.1%
HCWB's revenue has surged by 107% since the previous quarter and by 44% year-on-year
HCW Biologics's gross profit has soared by 107% from the previous quarter and by 44% YoY
The net income has dropped by 53% year-on-year and by 10% since the previous quarter
The operating income has dropped by 50% year-on-year and by 8% since the previous quarter

Growth

What is HCW Biologics's growth rate over time

Valuation

What is HCW Biologics stock price valuation
P/E
N/A
P/B
2.59
P/S
20.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
24.07
HCWB's EPS is down by 49% year-on-year and by 9% since the previous quarter
HCW Biologics's equity has plunged by 73% YoY and by 35% from the previous quarter
The P/B is 38% lower than the last 4 quarters average of 4.0
HCWB's revenue has surged by 107% since the previous quarter and by 44% year-on-year
HCWB's price to sales (P/S) is 78% less than its last 4 quarters average of 88.8

Efficiency

How efficient is HCW Biologics business performance
The ROA has shrunk by 116% YoY and by 20% QoQ
HCWB's return on invested capital has dropped by 72% year-on-year and by 16% since the previous quarter
HCWB's ROS is up by 47% since the previous quarter but it is down by 7% year-on-year
The ROE is down by 45% since the previous quarter

Dividends

What is HCWB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HCWB.

Financial health

How did HCW Biologics financials performed over time
HCWB's total assets is 40% greater than its total liabilities
HCWB's total liabilities has soared by 99% YoY and by 44% from the previous quarter
HCW Biologics's quick ratio has shrunk by 94% YoY and by 34% QoQ
The company's debt is 5% lower than its equity
HCW Biologics's debt to equity has surged by 102% QoQ
HCW Biologics's equity has plunged by 73% YoY and by 35% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.